Chen Liang Ph.D

Peptide-Drug Conjugates (PDCs) are rising as a key next-generation therapeutic avenue, combining the precise targeting of peptides with the potency of cytotoxic drugs to treat cancers and other diseases. Several challenges to this technology however include their clinical potential due to stability, ligand binding specificity and target affinity which remains a significant challenge. This workshop will provide insights into the future direction of PDCs as a promising application to unlock new targets and expand therapeutic applications.